

Grifols Donates \$1.4 Million in Hemophilia Blood Clotting Therapies to World Federation of Hemophilia

As part of its ongoing commitment to the global bleeding disorders community, Grifols' donation of plasma-derived blood clotting therapies will be used to treat patients in developing countries.

Barcelona, Spain (May 12, 2006). Grifols S.A., today announced that it will donate approximately \$ 1.4 million in blood clotting therapies to the World Federation of Hemophilia (WFH). The donated products include those used to treat both Hemophilia A and Hemophilia B and will be targeted for patients in developing countries where access to adequate treatment is often lacking. It is anticipated that this donation of hemophilia therapies will be used to treat hundreds of patients. The WFH will direct the distribution of the donated products to areas of greatest need.

“Through this donation, we hope that our therapies will reach the most needy patients,” said Victor Grifols, President and CEO of the company. “The mission of WFH is noble,” Grifols said, “and is consistent with the ethical values of our company.” Grifols produces plasma-derived hemophilia blood clotting therapies at its facilities in Barcelona, Spain and Los Angeles, California, USA. Its products are distributed in more than 90 countries around the world.

According to WFH President, Mark Skinner, one of aims of the organization's new vision – *Treatment for All* – is to improve the quality and supply of treatment products in developing countries. “The Grifols donation moves us one step closer to making our vision a reality,” said Skinner, “however, there is still a long way to go.” Ultimately, the WFH vision is to one day have treatment available for all those with inherited bleeding disorders regardless of where they live.

An estimated 400,000 people around the world have hemophilia. Yet, only 25% receive adequate treatment. Without treatment, many people with hemophilia suffer needlessly and die before they reach adulthood. With treatment, their life expectancy is close to that of someone without the condition.

Hemophilia is a lifelong bleeding disorder that prevents blood from clotting properly. People with hemophilia do not have enough clotting factor, a protein in blood that controls bleeding. Bleeding into joints and muscles can cause stiffness, pain, severe joint damage, disability, and sometimes death. People with more severe hemophilia require larger and more frequent doses of blood clotting factors. For more information about the WFH, hemophilia and other bleeding disorders go to www.WFH.org.

* * * *

About Grifols

Grifols has been present in healthcare since 1940, creating innovative products and services based on the values of ethics and responsibility. Grifols' activities focus on fulfilling the needs of healthcare professionals working in therapeutics, pharmacy, diagnostics and blood banking. For more than 60 years, Grifols has developed, manufactured and marketed products designed to improve human health. The Company manufactures products of proven efficacy, quality and safety. More information about Grifols can be found at www.grifols.com or contact:

Christopher Healey
Vice President, Government and Public Affairs
2111 Wilson Boulevard, Suite 700
Arlington, Virginia 22201
(703) 351-5004 phone
(703) 276-9052 fax
chris.healey@us.grifols.com